• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Industrials·001260.KS
Share

Namkwang Engineering & Construction Co., Ltd. Stocks

₩ 7450Last Updated 21.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

₩ 51.80M

₩ 7450
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Namkwang Engineering & Construction Co., Ltd. is a comprehensive construction firm delivering a wide array of services both domestically in South Korea and across international markets. The company's project expertise spans residential developments, including apartments, alongside commercial and business complexes, public and leisure facilities, and industrial factories and plants. They also undertake specialized cultural, historical, and other unique construction endeavors. Furthermore, Namkwang excels in significant infrastructure projects, encompassing roads, bridges, tunnels, subway and railway systems, water and sewerage networks, and maritime facilities such as harbors, dams, and ports. Established in 1947, the company maintains its headquarters in Yongin-si, South Korea.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, underpriced on P/

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.07.2026 21:08

Novo has filed a lawsuit against its competitor, Eli Lilly, over advertisements for weight-loss drugs

21.07.2026 20:21

Jefferies Forecasts Meta to Generate Billions in Revenue from AI Glasses. What Will Happen to the Stock?

21.07.2026 19:15

Stock of depression drugmaker Neuronetics adds 25% after BTIG initiation at 'buy'

21.07.2026 18:54

The U.S. president may impose new tariffs on dozens of countries this week — FT

21.07.2026 18:18

Chinese AI models have caught up with their American counterparts. Will Beijing now restrict access to them?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026